NeoGenomics Nabs Human Longevity’s Oncology Division for $37M
Xconomy
JANUARY 13, 2020
The division of San Diego-based Human Longevity generated approximately $10 million in revenue in 2019—an amount NeoGenomics (NASDAQ: NEO ) thinks it can grow by nearly 50 percent, says Charlie Eidson, investor relations and corporate development analyst, NeoGenomics.
Let's personalize your content